These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10195771)

  • 21. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
    McLain L; Durrani Z; Wisniewski LA; Porta C; Lomonossoff GP; Dimmock NJ
    Vaccine; 1996 Jun; 14(8):799-810. PubMed ID: 8817828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody to ovalbumin and delayed-type hypersensitivity to Candida albicans and mycobacteria in lactating Holstein cows using Quil A or Freund's complete adjuvant.
    Heriazon A; Thompson KA; Wilkie BN; Mathes-Sears W; Quinton M; Mallard BA
    Vet Immunol Immunopathol; 2009 Feb; 127(3-4):220-7. PubMed ID: 19054579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of adjuvant formulations on the induction of virus-neutralizing and virus-binding antibodies by chemosynthetic peptides of VP1 of foot-and-mouth-disease virus.
    Liebermann H; Bartels T; Reimann I; Mundt B
    Zentralbl Veterinarmed B; 1994 Apr; 41(2):139-44. PubMed ID: 7985430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice.
    Britt W; Fay J; Seals J; Kensil C
    J Infect Dis; 1995 Jan; 171(1):18-25. PubMed ID: 7798659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.
    Porta C; Spall VE; Loveland J; Johnson JE; Barker PJ; Lomonossoff GP
    Virology; 1994 Aug; 202(2):949-55. PubMed ID: 8030255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The effects of inoculation route and adjuvant type on the immunizing potency of CVB3 VP1 protein].
    Wen C; Gao ZY; Lan JM; Yan LJ; Chuai X; Li J; Li W; Wang YX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Oct; 27(10):1086-9. PubMed ID: 21968309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The development of cowpea mosaic virus as a potential source of novel vaccines.
    Porta C; Spall VE; Lin T; Johnson JE; Lomonossoff GP
    Intervirology; 1996; 39(1-2):79-84. PubMed ID: 8957673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1.
    Kabiri M; Sankian M; Hosseinpour M; Tafaghodi M
    Int J Pharm; 2018 Oct; 549(1-2):404-414. PubMed ID: 30075250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune responses and side effects of five different oil-based adjuvants in mice.
    Leenaars M; Koedam MA; Hendriksen CF; Claassen E
    Vet Immunol Immunopathol; 1998 Feb; 61(2-4):291-304. PubMed ID: 9613442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses.
    Rajananthanan P; Attard GS; Sheikh NA; Morrow WJ
    Vaccine; 1999 Feb; 17(7-8):715-30. PubMed ID: 10067677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.
    White K; Rades T; Kearns P; Toth I; Hook S
    Pharm Res; 2006 Jul; 23(7):1473-81. PubMed ID: 16779706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations.
    Flebbe LM; Braley-Mullen H
    Cell Immunol; 1986 Apr; 99(1):128-39. PubMed ID: 3489558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cowpea mosaic virus chimeric particles bearing ectodomain of matrix protein 2 (M2E) of influenza A virus: production and characteristics].
    Meshcheriakova IuA; El'darov MA; Migunov AI; Stepanova LA; Repko IA; Kiselev OI; Lomonosov DP; Skriabin KG
    Mol Biol (Mosk); 2009; 43(4):741-50. PubMed ID: 19807038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant effects of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and aluminium hydroxide on neutralizing antibody, antibody-isotype and delayed-type hypersensitivity responses to Semliki Forest virus in mice.
    Katz D; Lehrer S; Galan O; Lachmi BE; Cohen S
    FEMS Microbiol Immunol; 1991 Nov; 3(6):305-20. PubMed ID: 1812932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
    Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
    Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
    Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
    Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.
    Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H
    BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis.
    da Fonseca DP; Frerichs J; Singh M; Snippe H; Verheul AF
    Vaccine; 2000 Aug; 19(1):122-31. PubMed ID: 10924794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice.
    Babu JP; Pattnaik P; Gupta N; Shrivastava A; Khan M; Rao PV
    Vaccine; 2008 Aug; 26(36):4655-63. PubMed ID: 18640168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.